RTX, P&G and ResMed in Focus After New Updates

Raytheon, a business of RTX Corp. (RTX), has delivered its first Next Generation Jammer (NGJ) pods to the Royal Australian Air Force. The delivery is part of a collaborative development and production initiative between Australia and the U.S. Navy focused on airborne electronic warfare capabilities.

RTX is providing on-site support in Australia as the NGJ pods are fielded. This includes assistance tied to the rollout of the hardware, and it highlights how international defense programs can combine electronics, software, and long-cycle military contracts for the company.

According to commentary on the deal, the Australian handover reinforces RTX’s (RTX) position as a supplier in the electronic warfare niche and adds a reference customer for NGJ beyond the existing U.S. Navy relationship. Observers note that such programs can enhance long-term order visibility and associated service work.

The on-site support in Australia points to potential follow-on revenue from training, integration, and maintenance linked to the jammer pods, alongside possible future procurement decisions by other partners that may watch the Australian deployment.

RTX shares recently traded around US$196.42, compared with a consensus analyst target of about US$216 cited by Simply Wall St, placing the stock roughly 10% below that level and characterized as close to estimated fair value.

Social-media-based commentary compiled by Quiver Quantitative notes expectations of US$1.51 in EPS and US$21.46 billion in revenue for RTX’s (RTX) upcoming Q1 earnings release, following a 2.4% share price dip over the past month. Traders referenced technical levels near US$190 support and US$208 resistance while watching guidance and margins.

Quiver Quantitative highlights a US$268 billion RTX order backlog spanning missiles, engines, and electronics as a key strength, and reports Q4 2025 revenue of US$24.2 billion, up 12.09% year over year. Recent analyst reports tracked by the service show several buy or overweight ratings and a median price target of US$215.

Insider trading data from the same source show that, over the past six months, RTX insiders executed 14 open-market sales and no purchases, including sales by the CEO, CFO, and other senior executives. Separately, members of the U.S. Congress traded RTX five times in that period, with three purchases and two sales.

Procter & Gamble (PG) is presented across multiple reports as a defensive consumer staples company built on a focused portfolio of everyday brands in beauty, grooming, health care, fabric and home care, and baby, feminine and family care. Its model stresses high-margin essential products with recurring demand.

A Simply Wall St article notes that P&G’s Charmin brand and the company are partnering with the Arbor Day Foundation to plant an additional 1 million trees by 2030. This follows an earlier 1 million tree milestone tied to certified pulp and sustainable forestry practices.

The tree-planting program concentrates on restoring forests affected by natural disasters and environmental pressures, and is framed as linking Charmin tissue production and certified pulp use to measurable environmental outcomes. The partnership is cited as adding an ESG dimension to the P&G investment narrative.

The same source reports P&G’s share price at US$146.93, with a five-year return of 26.2%, a three-year return of 0.8%, and a one-year decline of 9.5%. These mixed share-price outcomes are described as context for evaluating the new sustainability commitment alongside financial metrics.

ResMed Inc. (RMD) is described as a leader in sleep and respiratory care, focusing on CPAP machines, masks, and related devices for obstructive sleep apnea, with additional products in oxygen therapy and ventilation. Its business blends device sales with recurring consumables and digital health platforms such as AirView and the myAir app.

An AD HOC NEWS report emphasizes that the United States is ResMed’s (RMD) largest and most profitable market, supported by rising diagnosis rates, aging demographics, obesity trends, and reimbursement coverage for CPAP therapies from Medicare and private insurers.

ResMed’s connected devices and cloud-based platforms are highlighted as creating a data-driven ecosystem for remote monitoring and patient engagement, and analysts cited in that article view the company positively for its market leadership and recurring revenue from consumables.

Separate coverage from Zacks, carried by Yahoo Finance and Yahoo’s yfinance feed, notes that ResMed has beaten consensus EPS estimates in its last two reported quarters, with an average surprise of 3.44%. It cites earnings of US$2.81 per share versus a US$2.69 estimate most recently, and US$2.55 versus US$2.49 in the prior quarter.

Zacks reports that ResMed currently has an Earnings ESP of +0.63% and a Zacks Rank #3 (Hold). Their research associates this combination with a higher probability of another earnings beat, and they state that the company’s next earnings report is expected on April 30, 2026.

A Simply Wall St analysis of Boeing (BA) notes that the stock recently traded around US$223.38 and has gained 40.2% over the past year, despite a 1.9% year-to-date decline and a five-year return of negative 7.5%. The article states that Boeing’s (BA) current price implies about 29.4% undervaluation relative to a discounted cash flow estimate of US$316.23 per share.

The same report contrasts that DCF-based view with valuation checks showing Boeing trading on a P/E of 92.93x, compared with an Aerospace & Defense industry average P/E of 39.61x and a peer group average of 31.50x. Simply Wall St’s proprietary Fair Ratio for Boeing is cited at 65.93x, leading the service to describe the stock as overvalued on that earnings-based measure.

Across the broader set of articles, other large caps including Travelers, 3M (MMM), Bristol-Myers Squibb (BMY), Pfizer (PFE), Danaher, Hasbro (HAS), eBay (EBAY), Packaging Corp of America, Genuine Parts and Procter & Gamble (PG) are profiled as portfolio candidates, but without new single-date corporate events comparable to the RTX, P&G ESG, ResMed and Boeing updates outlined above.